Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 6, 2024, reports on the conclusion of a specific share repurchase programme initiated on May 6, 2024. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing details transactions related to the company's broader capital allocation strategy.
Key Financial Metrics
The filing focuses exclusively on share repurchase activities and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
- Specific Programme Value: The programme running from May 7, 2024, to August 5, 2024, concluded with a total transaction value of DKK 2,199,971,278 (approximately DKK 2.2 billion).
- Shares Repurchased (Specific Programme): 2,332,876 B shares were repurchased under this specific tranche.
- Cumulative Repurchases (Since Feb 6, 2024): As of August 5, 2024, the company has repurchased a total of 11,067,126 B shares.
- Cumulative Value (Since Feb 6, 2024): The total transaction value for the period starting February 6, 2024, is DKK 9,727,706,050.
- Average Price (Cumulative): The average share price for repurchases since February 6, 2024, is DKK 878.97 per B share.
- Treasury Shares: The company now holds 12,432,916 B shares as treasury shares, representing 0.3% of the total share capital.
Material Changes
The primary material change reported is the completion of the DKK 2.2 billion share repurchase tranche. The filing provides a transaction log showing daily repurchase volumes and average prices between July 29, 2024, and August 5, 2024, with average prices ranging from DKK 843.90 to DKK 912.52 during this specific window.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk maintains an overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning February 6, 2024. As of August 5, 2024, approximately DKK 9.73 billion of this total authorization has been utilized.
Risks and Contingencies: The filing does not disclose new risks, contingencies, or unusual items. It references compliance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining authorization under the DKK 20 billion total repurchase programme (approximately DKK 10.27 billion remaining as of August 5, 2024).
- Confirm the total number of treasury shares held (12,432,916 B shares) and its impact on earnings per share calculations.
- Review the detailed transaction log on novonordisk.com for granular pricing data beyond the summary provided.
- Note that this filing contains no operational financial results (revenue, net income) for the period; refer to the most recent Form 20-F or quarterly reports for those metrics.